• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 26, 2013

View Archived Issues

Onconova, Conatus Price IPOs: $78M, $66M, Both with Upside

Onconova Therapeutics Inc. priced its shares higher than expected in an initial public offering (IPO), and Conatus Pharmaceuticals Inc., also pricing, rolled out 1 million more shares than originally targeted, to settle in the midrange of the targeted cost per share. Read More

Adimab Hooks GSK, Expands Biogen Alliance

Despite the proliferation of biotech initial public offerings (IPO) this year – including two that priced yesterday (see the related story in this issue) – Adimab LLC is distinctly disinterested in the public markets. And the Lebanon, N.H., firm can well afford to remain private. Early Friday morning, the company disclosed two more in a string of lucrative deals that catapulted it to profitability just three years after its 2007 launch. Read More

With Current Valuations M&As are Scarce

Mergers and acquisitions have always been a regular staple in the biotech industry . . . until this year that is. Can it be possible that there won't be at least one blockbuster deal executed by the end of December? Read More

Shared REMS an Issue for Standardization

If the FDA wants innovators to share their risk evaluation and management strategies (REMS) with competitors, it needs to come up with guidance, and possibly incentives, to ensure fair play, a former FDA attorney told the agency Thursday as it kicked off a two-day public meeting on how best to standardize and evaluate REMS. Read More

Biogen Idec Excels on Tecfidera Launch

Biogen Idec Inc., of Weston, Mass., blasted consensus sales estimates for multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate) out of the water, turning in $192 million in its second quarter earnings, compared to the $75 million expected by the street. The company's total revenues were $1.7 billion for the second quarter, up 21 percent over the second quarter of 2012. Read More

Tumor Suppressor PTEN Is Suddenly All over the Place

The tumor suppressor PTEN is "probably second only to P53 in the number of deletions and mutations we see in cancer," Vuk Stambolic told BioWorld Today. Read More

Other News To Note

• Provectus Pharmaceuticals Inc., of Knoxville, Tenn., said an article published in PLOS One, based on a study conducted at the Moffitt Cancer Center examining the immunologic mechanism of PV-10 in murine models of breast cancer and melanoma, concluded intralesional administration of the drug reduced the growth of directly injected tumors and led to the induction of a robust antitumor T-cell response. Read More

Clinic Roundup

• Adaptimmune Ltd., of Oxford, UK, opened a Phase I/IIa, multiple-site, two-cohort, open-label trial in ovarian cancer at Roswell Park Cancer Institute in Buffalo, N.Y., and City of Hope in Duarte, Calif. Researchers will investigate the safety, bioactivity and effectiveness of treating patients with their own T cells after genetically engineering the cells to enhance their antitumor properties. Read More

Pharma: Other News To Note

• Teva Pharmaceutical Industries Ltd., of Jerusalem, and Lonza Group, of Basel, Switzerland, said they decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars following a strategic review of the Teva-Lonza Joint Venture. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • White puzzle pieces on blue background

    Highridge sells bone healing business to Avista

    BioWorld MedTech
    In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division to Avista Healthcare Partners. The...
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe